Proposed Acquisition of ResApp Health by Pfizer Australia Holdings Pty Limited, a wholly-owned subsidiary of Pfizer Inc, for $0.208 cash per share by scheme of arrangement.
Your Vote is Important
Your Directors unanimously recommend that you vote in favour of the Scheme, in the absence of a Superior Proposal and subject to the Independent Expert continuing to conclude that the Scheme is in the best interests of ResApp Health Shareholders.
The Independent Expert has concluded that the Scheme is in your best interests, in the absence of a superior proposal.
The key events and the expected timing in relation to the approval and implementation of the Scheme are set out in the table below.
2:00pm (AEST) on 31 August 2022
Latest time and date for lodgement of completed Proxy Form for the Scheme Meeting
7:00pm (AEST) on 31 August 2022
Time and date for determining eligibility of ResApp Shareholders to vote at the Scheme Meeting
2:00pm (AEST) on 2 September 2022
Time and date of the Scheme Meeting
Note: All stated dates and times are indicative only. The actual timetable will depend on many factors outside the control of ResApp and Pfizer Australia, including the Court approval process and the satisfaction or waiver of the conditions precedent to the completion of the Scheme by each of ResApp and Pfizer Australia. ResApp has the right to vary the timetable detailed below subject to the approval of such variation by Pfizer Australia, the Court and ASIC where required. Any changes to the above timetable will be announced to ASX and will be available under ResApp's profile on ASX at www.asx.com.au.